{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:06:34Z","timestamp":1773194794415,"version":"3.50.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA) PET is used to guide postprostatectomy salvage radiotherapy (SRT) and enable intensification through dose escalation and target modification. The oncologic benefit and safety profile of PSMA PET\u2013guided intensification remain uncertain. We aimed to synthesize comparative and single-arm evidence on oncologic outcomes and toxicity of PSMA PET\u2013guided intensification of postprostatectomy SRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic review and meta-analysis following PRISMA 2020 guidelines. PubMed, Web of Science, Scopus, Embase and Cochrane Library were searched from inception to 26 December 2025. Comparative and single-arm studies evaluating PSMA PET\u2013guided intensification of postprostatectomy SRT were included. We included clinical studies using PSMA PET\/CT or PET\/MRI to guide radiotherapy intensification and excluded preclinical studies and non-original reports. Primary outcomes were failure-free survival (FFS) and biochemical recurrence\u2013free survival (bRFS). Secondary outcomes included metastasis- and survival-related endpoints, treatment escalation, and toxicity. Meta-analysis was conducted only when sufficient comparative data were available. Hazard ratios were pooled in RevMan 5.4.1 using fixed- or random-effects models according to heterogeneity. Risk of bias was assessed with the Newcastle\u2013Ottawa Scale. Statistical significance was set at two-sided P&amp;lt;0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen studies met inclusion criteria, including five comparative and ten single-arm studies. Two studies reported FFS-type endpoints; because only two studies were available and endpoint definitions differed substantially, these findings were summarized descriptively. Four comparative studies involving 692 patients contributed to bRFS meta-analysis. PSMA PET\u2013guided SRT showed numerically improved bRFS versus standard SRT, but the difference was not statistically significant (pooled HR 0.61, 95% CI 0.33\u20131.13; P = 0.12; I\u00b2=55%). Other secondary oncologic outcomes were variably reported with limited events and were synthesized descriptively. Severe genitourinary or gastrointestinal toxicity was uncommon, and some studies suggested delayed treatment escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PSMA PET\u2013guided intensification of postprostatectomy SRT may improve biochemical control without an increase in severe toxicity; however, a statistically significant bRFS benefit was not demonstrated and evidence for other oncologic outcomes remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261277044.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1779689","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:28:47Z","timestamp":1773120527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA PET\u2013guided intensification of postprostatectomy salvage radiotherapy for prostate cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Geng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology Surgery,The First People\u2019s Hospital of Jiande","place":["Jiande, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery,The First People\u2019s Hospital of Jiande","place":["Jiande, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaobao","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery,The First People\u2019s Hospital of Jiande","place":["Jiande, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery,The First People\u2019s Hospital of Jiande","place":["Jiande, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery,The First People\u2019s Hospital of Jiande","place":["Jiande, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03714","article-title":"Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death","volume":"39","author":"Tilki","year":"2021","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage Therapy for Prostate Cancer: AUA\/ASTRO\/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e253746","DOI":"10.1001\/jamaoncol.2025.3746","article-title":"Prostate-specific membrane antigen PET-guided intensification of salvage radiotherapy after radical prostatectomy: A phase 2 randomized clinical trial","volume":"2","author":"Belliveau","year":"2025","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B13","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022)","author":"Higgins","year":"2022"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.8165","article-title":"18F-DCFPyL PSMA-PET affects management of salvage radiotherapy for post-prostatectomy patients with biochemical failure: A matched cohort study","volume":"17","author":"Arifin","year":"2023","journal-title":"Can Urol Assoc J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13550-016-0233-4","article-title":"Impact of 68Ga-PSMA PET\/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy","volume":"6","author":"Bluemel","year":"2016","journal-title":"EJNMMI Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2025.07.003","article-title":"Volumetric changes and acute toxicity with 68Ga prostate-specific membrane antigen versus 18F-fluciclovine positron emission tomography\/computer tomography guided postprostatectomy radiation: final analysis of a randomized trial","volume":"28","author":"Dhere","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ctro.2022.07.001","article-title":"A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial","volume":"36","author":"Gunnlaugsson","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"10:e60323","DOI":"10.2196\/60323","article-title":"A machine learning approach for predicting biochemical outcome after PSMA-PET-guided salvage radiotherapy in recurrent prostate cancer after radical prostatectomy: retrospective study","author":"Janbain","year":"2024","journal-title":"JMIR Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.12.003","article-title":"18F-fluciclovine or 68Ga-PSMA-11 molecular imaging to guide dose escalation of salvage radiotherapy after radical prostatectomy for prostate cancer: the EMPIRE-2 trial","author":"Jani","year":"2025","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.640467","article-title":"Combining 68Ga-PSMA-PET\/CT-directed and elective radiation therapy improves outcome in oligorecurrent prostate cancer: A retrospective multicenter study","volume":"11","author":"Kirste","year":"2021","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05557-z","article-title":"Outcome after PSMA-PET\/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy","volume":"49","author":"Rogowski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.212563","article-title":"Outcome after PSMA PET\/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis","volume":"60","author":"Schmidt-Hegemann","year":"2019","journal-title":"J Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05931-5","article-title":"The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis","volume":"50","author":"Spohn","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194956","article-title":"Dose-escalated salvage radiotherapy for macroscopic local recurrence of prostate cancer in the prostate-specific membrane antigen positron emission tomography era","volume":"14","author":"Tamihardja","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06802-x","article-title":"Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis","volume":"51","author":"Trapp","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111215","article-title":"Phase II study of salvage HDR brachytherapy combined with external beam radiotherapy for isolated prostate bed relapse after radical prostatectomy: preliminary clinical results","volume":"213","author":"Vall\u00e9s","year":"2025","journal-title":"Radiother Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.715020","article-title":"Feasibility and outcome of PSMA-PET-based dose-escalated salvage radiotherapy versus conventional salvage radiotherapy for patients with recurrent prostate cancer","volume":"11","author":"Vogel","year":"2021","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.eururo.2024.01.012","article-title":"Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography on prostate cancer salvage radiotherapy management: results from a prospective multicenter randomized phase 3 trial (PSMA-SRT NCT03582774)","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15101224","article-title":"Detection rates of PSMA-PET radiopharmaceuticals in recurrent prostate cancer: A systematic review","volume":"15","author":"Rais-Bahrami","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2022.05.004","article-title":"PEARLS: is our use of prostate-specific membrane antigen positron emission tomography-computed tomography meaningful for our patients","volume":"34","author":"Murray","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003891","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051329","article-title":"Impact of three-month androgen deprivation therapy on [68Ga]Ga-PSMA-11 PET\/CT indices in men with advanced prostate cancer-results from a pilot prospective study","volume":"14","author":"Tseng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001966","article-title":"Flare on serial prostate-specific membrane antigen-targeted 18F-DCFPyL PET\/CT examinations in castration-resistant prostate cancer: first observations","volume":"43","author":"Zukotynski","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04945-1","article-title":"False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial","volume":"48","author":"Fendler","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.06.004","article-title":"Biochemical recurrence in prostate cancer: the european association of urology prostate cancer guidelines panel recommendations","volume":"6","author":"Van den Broeck","year":"2020","journal-title":"Eur Urol Focus"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02741","article-title":"Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer: analysis of NRG oncology\/RTOG 9601","volume":"40","author":"Jackson","year":"2022","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"43:100684","DOI":"10.1016\/j.ctro.2023.100684","article-title":"ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy","author":"Dirix","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1779689\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:28:49Z","timestamp":1773120529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1779689\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":46,"alternative-id":["10.3389\/fonc.2026.1779689"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1779689","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1779689"}}